UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number: 001-39516 Owlet, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 85-1615012 | | --- | --- | | ...

Owlet, Inc. (NYSE:OWLT) Q3 2021 Results Conference Call November 10, 2021 4:30 PM ET Company Participants Mike Cavanaugh - Investor Relations Kurt Workman - Co-Founder and Chief Executive Officer Kate Scolnick - Chief Financial Officer Conference Call Participants Charles Rhyee - Cowen & Co John Babcock - Bank of America Jim Suva - Citigroup Operator Hello everyone and welcome to Owlet Q3 2021 Earnings Call. My name is [Nadia] and I will be coordinating your call today. [Operator Instructions] I will now ha ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________ Commission File No. 001-39516 OWLET, INC. (Exact name of registrant as specified in its charter) (State or other jurisdict ...

Financial Data and Key Metrics Changes - Total revenues for Q2 2021 were $24.9 million, representing a year-over-year increase of 36% and a sequential increase of 14% from Q1 2021 [19] - Gross margins were 54.2%, an increase of 600 basis points compared to 48.2% in Q2 2020 [20] - Operating loss for Q2 was $5.9 million, compared to $0.6 million in Q2 2020 [21] - Net loss in Q2 was $5.3 million, compared to $1.1 million in Q2 2020 [22] - EBITDA loss for Q2 2021 was $4.6 million, with an EBITDA margin of negative 18.4% [22] Business Line Data and Key Metrics Changes - Revenue growth was primarily driven by the flagship Smart Sock and Monitor Duo products [19] - Approximately $2.2 million of Q2 2020 revenues were related to initial sales of new inventory for Smart Sock version three and Monitor Duo version three [20] Market Data and Key Metrics Changes - International sales accounted for 7% of total revenue, the highest percentage to date [13] - Traffic to the company's website in July was up over 50% year-over-year [12] Company Strategy and Development Direction - The company aims to deepen market penetration in the U.S., expand globally, and enhance the Owlet ecosystem with integrated services [10][17] - The company is focused on increasing awareness and accessibility of its products through aggressive marketing strategies [11][31] - OwletCare platform represents an $81 billion market opportunity, with a goal to drive over $1 billion in revenue by 2025 [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving revenue goals for 2021, projecting approximately $107 million in revenues [23] - The company is confident in its ability to navigate supply chain challenges while maintaining gross margin improvements [38] Other Important Information - The company raised $135 million in capital through its public company business combination, strengthening its balance sheet for future investments [22] - The Smart Sock Plus was launched, extending the product's age range from 18 months to five years [14] Q&A Session Summary Question: How will the company deploy the $135 million raised? - The company plans to focus on deepening U.S. market penetration, expanding internationally, and enhancing the connected nursery ecosystem [28] Question: What is the current adoption rate in states with over 20% penetration? - Awareness is the main driver for adoption, and the company is increasing marketing efforts to boost awareness [31] Question: What is the timeline for FDA approval and insurance reimbursement? - The company is confident in its FDA submission progress and plans to work with insurance for reimbursement after approval [39]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________ Commission File No. 001-39516 SANDBRIDGE ACQUISITION CORPORATION (Exact name of registrant as specified in its charter) (State or other jur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: Sandbridge Acquisition Corporation (Exact name of registrant as specified in its charter) Delaware 85-1615012 (State or other jurisdicti ...

Financial Performance - The company reported a net loss of $30,155 for the three months ended September 30, 2020, with operating costs of $36,307 and interest income of $6,152 from marketable securities[96]. - The company has not engaged in any operations or generated revenues to date, with all activities focused on preparing for the IPO and searching for a target company[95]. Initial Public Offering (IPO) - The company completed its Initial Public Offering on September 17, 2020, raising gross proceeds of $230,000,000 from the sale of 23,000,000 Units at $10.00 per Unit, including an over-allotment option[98]. - The company incurred $12,948,806 in transaction costs related to the IPO, which included $4,204,000 in underwriting fees and $8,050,000 in deferred underwriting fees[100]. Trust Account and Cash Management - Following the IPO, the company placed $230,000,000 in a Trust Account and had $1,977,519 in cash available for working capital purposes[100]. - As of September 30, 2020, the company had cash and marketable securities in the Trust Account totaling $230,006,152, intended for use in completing a Business Combination[102]. - The company had cash of $1,438,624 outside the Trust Account as of September 30, 2020, primarily for identifying and evaluating target businesses[103]. Debt and Financing - The company does not have any long-term debt or capital lease obligations, only a monthly fee of $10,000 to an affiliate of the Sponsor for administrative support[107]. - The company may need additional financing to complete a Business Combination or to cover redemptions of public shares, which could involve issuing additional securities or incurring debt[105]. Off-Balance Sheet Arrangements - The company has no off-balance sheet arrangements as of September 30, 2020[106].